Guardant Health, INC Form 4 insider transactions

NASDAQ
Director Steve Krognes reports the vesting and conversion of restricted stock units into common stock of Guardant Health, Inc.
NASDAQ
Tariq Musa, a director at Guardant Health, sold 116 shares of common stock at a price of $34.85 per share on December 18, 2024.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of 1,020 shares and the disposal of 535 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Director Myrtle S. Potter of Guardant Health, Inc. reports the vesting of restricted stock units and subsequent disposal of shares.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and subsequent tax withholding transactions.
NASDAQ
Guardant Health's Chief Commercial Officer, Chris Freeman, reported the acquisition of 1,402 shares and the disposal of 597 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Craig Eagle, Chief Medical Officer of Guardant Health, reported the acquisition of 1,402 shares and the disposal of 711 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Guardant Health's Chief Financial Officer, Michael Bell, reported the acquisition and disposal of company stock and restricted stock units on December 15, 2024.
NASDAQ
Director Tariq Musa of Guardant Health, Inc. engaged in stock transactions, including the sale of 2,320 shares and the vesting of 250 restricted stock units.
NASDAQ
Director Meghan Joyce of Guardant Health acquired 67 shares of common stock through the vesting of restricted stock units.
NASDAQ
Meghan V. Joyce, a director at Guardant Health, sold 100 shares of common stock on December 2, 2024.
NASDAQ
John G. Saia, Chief Legal Officer of Guardant Health, Inc., reported the acquisition and disposal of company stock and restricted stock units on December 1, 2024.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, reported the acquisition of 710 shares of common stock and the disposal of 360 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Darya Chudova, Chief Technology Officer of Guardant Health, reported the acquisition and disposal of company stock and restricted stock units on December 1, 2024.
NASDAQ
Director Steve Krognes of Guardant Health, Inc. reported the acquisition of 154 shares of common stock through the vesting of restricted stock units.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, sold 7,000 shares of common stock at an average price of $29.246 per share on November 18, 2024.
NASDAQ
Director Tariq Musa of Guardant Health acquired 250 shares of common stock and 250 restricted stock units through vesting on November 15, 2024.
NASDAQ
Myrtle S. Potter, a director at Guardant Health, acquired 68 shares of common stock through the vesting of restricted stock units.
NASDAQ
Meghan V. Joyce, a director at Guardant Health, sold 2,896 shares of common stock at an average price of $29.9017 per share.
NASDAQ
Director Ian T. Clark of Guardant Health executed multiple stock transactions, including option exercises and sales, and transferred shares to a family trust.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, was granted stock options and restricted stock units on November 8, 2024, as reported in a Form 4 filing.
NASDAQ
Terilyn J. Monroe, Chief People Officer at Guardant Health, was granted stock options and restricted stock units on November 8, 2024.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, received stock options and restricted stock units as part of a compensation package.
NASDAQ
Guardant Health's Chief Commercial Officer, Chris Freeman, received stock options and restricted stock units as part of his compensation package.
NASDAQ
Craig Eagle, Chief Medical Officer of Guardant Health, was granted stock options and restricted stock units on November 8, 2024, as part of his compensation.
NASDAQ
Darya Chudova, Chief Technology Officer of Guardant Health, was granted stock options and restricted stock units on November 8, 2024, as part of her compensation.
NASDAQ
Guardant Health's Chief Financial Officer, Michael Bell, received stock options and restricted stock units on November 8, 2024, as part of his compensation.
NASDAQ
Director Roberto Mignone of Guardant Health, Inc. acquired stock options and restricted stock units on November 8, 2024, as part of a compensation package.
NASDAQ
Director Meghan Joyce reports the vesting and subsequent disposition of restricted stock units in Guardant Health, Inc.
NASDAQ
Darya Chudova, Chief Technology Officer of Guardant Health, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.